PMID- 36322291
OWN - NLM
STAT- MEDLINE
DCOM- 20221129
LR  - 20230310
IS  - 1724-6059 (Electronic)
IS  - 1121-8428 (Print)
IS  - 1121-8428 (Linking)
VI  - 35
IP  - 9
DP  - 2022 Dec
TI  - Transcription factor NRF2 as potential therapeutic target for preventing muscle 
      wasting in aging chronic kidney disease patients.
PG  - 2215-2225
LID - 10.1007/s40620-022-01484-w [doi]
AB  - Increased muscle protein catabolism leading to muscle wasting is a prominent 
      feature of the syndrome of protein-energy wasting (PEW) in patients with chronic 
      kidney disease (CKD). PEW and muscle wasting are induced by factors such as 
      inflammation, oxidative stress and metabolic acidosis that activate the 
      ubiquitin-proteasome system, the main regulatory mechanism of skeletal muscle 
      degradation. Whether deficiency of nuclear factor erythroid 2-related factor 2 
      (NRF2), which regulates expression of antioxidant proteins protecting against 
      oxidative damage triggered by inflammation, may exacerbate PEW has yet to be 
      examined in aging patients with CKD. This review focuses on the hypothesis that 
      NRF2 is involved in the maintenance of muscle mass and explores whether sustained 
      activation of NRF2 by non-pharmacological interventions using nutraceutical 
      activators to improve redox homeostasis could be a plausible strategy to prevent 
      skeletal muscle disorders, including muscle wasting, sarcopenia and frailty 
      associated with PEW in aging CKD patients.
CI  - (c) 2022. The Author(s).
FAU - Gomez-Garcia, Erika F
AU  - Gomez-Garcia EF
AD  - Unidad de Investigacion Biomedica 02, Hospital de Especialidades, Centro Medico 
      Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
AD  - Unidad de Investigacion Biomedica 01, Centro de Investigacion Biomedica de 
      Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
AD  - Facultad de Medicina y Psicologia, Universidad Autonoma de Baja California, 
      Tijuana, Mexico.
FAU - Del Campo, Fabiola Martin
AU  - Del Campo FM
AD  - Unidad de Investigacion Biomedica 02, Hospital de Especialidades, Centro Medico 
      Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
FAU - Cortes-Sanabria, Laura
AU  - Cortes-Sanabria L
AD  - Unidad de Investigacion Biomedica 02, Hospital de Especialidades, Centro Medico 
      Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
FAU - Mendoza-Carrera, Francisco
AU  - Mendoza-Carrera F
AD  - Unidad de Investigacion Biomedica 01, Centro de Investigacion Biomedica de 
      Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
FAU - Avesani, Carla Maria
AU  - Avesani CM
AD  - Renal Medicine and Baxter Novum, Clintec, Karolinska Institutet, M99 Karolinska 
      University Hospital Huddinge, 14186, Stockholm, Sweden.
FAU - Stenvinkel, Peter
AU  - Stenvinkel P
AD  - Renal Medicine and Baxter Novum, Clintec, Karolinska Institutet, M99 Karolinska 
      University Hospital Huddinge, 14186, Stockholm, Sweden.
FAU - Lindholm, Bengt
AU  - Lindholm B
AUID- ORCID: 0000-0003-4269-4293
AD  - Renal Medicine and Baxter Novum, Clintec, Karolinska Institutet, M99 Karolinska 
      University Hospital Huddinge, 14186, Stockholm, Sweden. bengt.lindholm@ki.se.
FAU - Cueto-Manzano, Alfonso M
AU  - Cueto-Manzano AM
AD  - Unidad de Investigacion Biomedica 02, Hospital de Especialidades, Centro Medico 
      Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221102
PL  - Italy
TA  - J Nephrol
JT  - Journal of nephrology
JID - 9012268
RN  - 0 (NF-E2-Related Factor 2)
SB  - IM
MH  - Humans
MH  - *NF-E2-Related Factor 2/metabolism
MH  - Muscular Atrophy/etiology/prevention & control
MH  - *Renal Insufficiency, Chronic/complications/therapy/metabolism
MH  - Cachexia/complications/metabolism/pathology
MH  - Aging
MH  - Muscle, Skeletal/metabolism
MH  - Inflammation/complications
PMC - PMC9700608
OTO - NOTNLM
OT  - Chronic kidney disease
OT  - Inflammation
OT  - Muscle wasting
OT  - NRF2
OT  - Oxidative stress
COIS- BL was employed by Baxter Healthcare Corporation. None of the other authors 
      declare relevant financial interests that would represent a conflict of interest.
EDAT- 2022/11/03 06:00
MHDA- 2022/11/30 06:00
PMCR- 2022/11/02
CRDT- 2022/11/02 12:19
PHST- 2022/07/19 00:00 [received]
PHST- 2022/10/01 00:00 [accepted]
PHST- 2022/11/03 06:00 [pubmed]
PHST- 2022/11/30 06:00 [medline]
PHST- 2022/11/02 12:19 [entrez]
PHST- 2022/11/02 00:00 [pmc-release]
AID - 10.1007/s40620-022-01484-w [pii]
AID - 1484 [pii]
AID - 10.1007/s40620-022-01484-w [doi]
PST - ppublish
SO  - J Nephrol. 2022 Dec;35(9):2215-2225. doi: 10.1007/s40620-022-01484-w. Epub 2022 
      Nov 2.